4,4’-difluoro-[1,1’-biphenyl]-2-carboxylic acid | 1841-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4’-difluoro-[1,1’-biphenyl]-2-carboxylic acid
• 英文别名: 4,4'-Difluoro-2-biphenylcarbonsaeure；4,4'-Difluor-2-biphenylcarbonsaeure；4,4'-difluoro-biphenyl-2-carboxylic acid；4,4'-Difluoro-[1,1'-biphenyl]-2-carboxylic acid；5-fluoro-2-(4-fluorophenyl)benzoic acid
• CAS: 1841-44-7
• 化学式: C₁₃H₈F₂O₂
• 分子量: 234.202
• InChiKey: CHQPXZPHDTZKPT-UHFFFAOYSA-N

物化性质

• 熔点：
  124 °C
• 沸点：
  336.2±27.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4’-difluoro-[1,1’-biphenyl]-2-carboxylic acid 在 platinum(IV) oxide 4-二甲氨基吡啶 、 氯化亚砜 、 氯仿 、 氢气 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 20.0~79.0 ℃ 、344.74 kPa 条件下， 反应 0.25h， 生成 N-[2-(2,7-difluoro-9H-fluoren-9-yl)ethyl]propanamide
  参考文献：
  名称：

  Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides

  摘要：

  A series of fluoren-9-yl ethyl amides (2) were synthesized and evaluated for human melatonin MT1 and MT2 receptor binding. N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]propanamide (2b) was selected and evaluated in functional assays measuring intrinsic activity at the human MT1 and MT2 receptors and demonstrated full agonism at both receptors. The chronobiotic properties of 2b were demonstrated in both acute and chronic rat models where 2b produced an acute phase advance of 32 min at 1 mg/kg and chronically entrained free-running rats with a mean effective dose of 0.23 mg/kg. Compound 2b is significantly less efficacious than melatonin in constricting human coronary artery. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.002
• 作为产物：
  描述：

  2-溴-5-氟苯甲酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) sodium hydroxide 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 生成 4,4’-difluoro-[1,1’-biphenyl]-2-carboxylic acid
  参考文献：
  名称：

  Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides

  摘要：

  A series of fluoren-9-yl ethyl amides (2) were synthesized and evaluated for human melatonin MT1 and MT2 receptor binding. N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]propanamide (2b) was selected and evaluated in functional assays measuring intrinsic activity at the human MT1 and MT2 receptors and demonstrated full agonism at both receptors. The chronobiotic properties of 2b were demonstrated in both acute and chronic rat models where 2b produced an acute phase advance of 32 min at 1 mg/kg and chronically entrained free-running rats with a mean effective dose of 0.23 mg/kg. Compound 2b is significantly less efficacious than melatonin in constricting human coronary artery. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.002

文献信息

• [EN] BENZAZEPINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAZÉPINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2019004421A1

  公开（公告）日：2019-01-03

  The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is -C(=O)-NH-, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.

  本发明提供了具有抗利尿激素V1a和V2拮抗作用的新型苯并哌啶化合物的结构式（1）或其盐，以及其医药用途。在该式中，R1是可选取代的C1-6烷基等；L是-C(=O)-NH-等；环A1是一个碳氢环等；环A2是一个碳氢环等；环A1和环A2中的每一个可能具有至少一个取代基。
• Heterocyclic amide compounds as apolipoprotein b inhibitors
  申请人：Takasugi Hisashi

  公开号：US20050038035A1

  公开（公告）日：2005-02-17

  The present invention relates to a compound of the formula (I) wherein R 1 is optionally substituted aryl; R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A 1 ) m1 -(A 2 ) m2 -; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及一种化合物，其分子式为（I），其中R1为可选取代芳基；R2为可选取代芳基、可选取代杂环芳基、可选取代较低环烷基、可选取代芳氧基、可选取代芳基磺酰基、乙烯基、氨基甲酰基、保护羧基或保护氨基；环A为由可选取代芳基或可选取代杂环芳基衍生的二价残基；X为由环烷烯、萘、不饱和的5或6元杂单环基衍生的二价残基，每种残基均可选取代，以及取代苯基；Y为-(A1)m1-(A2)m2-；Z为直接键或哌嗪，或其盐。本发明的化合物及其盐能抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于高循环Apo B水平引起的疾病或病症的药物。
• Substituierte Biphenylcarbonsäuren, Verfahren zu ihrer Herstellung und neue Zwischenprodukte
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0396014A2

  公开（公告）日：1990-11-07

  Neue Biphenylcarbonsäuren der Formel I worin R¹ die angegebenenen Bedeutungen hat und ein Verfahren zu ihrer Herstellung werden beschrieben.

  描述了式 I 的新联苯羧酸（其中 R¹ 的含义已给出）及其制备方法。 中 R¹ 的含义及其制备方法。
• Benzazepine derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10889570B2

  公开（公告）日：2021-01-12

  The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.

  本发明提供了具有血管加压素V1a和V2拮抗作用的式(1)的新型苯并氮杂卓化合物或其盐及其医疗用途。 式中，R1为任选取代的C1-6烷基等；L为-C(═O)-NH-等；环A1为烃环等；环A2为烃环等；环A1和环A2各自可具有至少一个取代基。
• Semisynthetic Penicillins. I. 2-Biphenylylpenicillins
  作者：J. R. E. Hoover、A. W. Chow、R. J. Stedman、N. M. Hall、H. S. Greenberg、M. M. Dolan、R. J. Ferlauto

  DOI：10.1021/jm00333a001

  日期：1964.5